Related Experiment Video
Updated: May 9, 2026
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans
Jennifer L A Rabjohns1, Yoon-Dong Park1, Jean Dehdashti2
1Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Abstract:
Cryptococcus neoformans is a pathogenic fungus that causes meningitis worldwide, particularly in human immunodeficiency virus (HIV)-infected individuals. Although amphotericin B is the "gold standard" treatment for cryptococcal meningitis, the toxicity and inconvenience of intravenous injection emphasize a need for development of new anticryptocccal drugs. Recent data from humans and animal studies suggested that a nutrient-deprived host environment may exist in cryptococcal meningitis. Thus, a screening assay for identifying fungicidal compounds under nutrient-deprived conditions may provide an alternative strategy to develop new anticryptococcal drugs for this disease. A high-throughput fungicidal assay was developed using a profluorescent dye, alamarBlue, to detect residual metabolic activity of C. neoformans under nutrient-limiting conditions. Screening the Library of Pharmacologically Active Compounds (LOPAC) with this assay identified a potential chemical scaffold, 10058-F4, that exhibited fungicidal activity in the low micromolar range. These results thus demonstrate the feasibility of this alamarBlue-based assay for high-throughput screening of fungicidal compounds under nutrient-limiting conditions for new anticryptococcal drug development.
Insights
Researchers developed a new assay to find antifungal drugs for cryptococcal meningitis. This method identifies compounds effective in nutrient-poor environments, offering a novel strategy for drug discovery against this serious infection.
Area of Science:
- Mycology
- Infectious Diseases
- Drug Discovery
Background:
- Cryptococcus neoformans causes meningitis globally, especially in HIV-infected individuals.
- Current treatment (amphotericin B) has toxicity and administration challenges, necessitating new drug development.
- Host environments in cryptococcal meningitis may be nutrient-deprived, suggesting a target for drug screening.
Purpose of the Study:
- To develop and validate a high-throughput screening assay for identifying fungicidal compounds under nutrient-limiting conditions.
- To discover novel chemical scaffolds with anticryptococcal activity using this assay.
- To demonstrate the feasibility of nutrient-deprived screening for developing new drugs against cryptococcal meningitis.
Main Methods:
- Developed a high-throughput fungicidal assay using the alamarBlue profluorescent dye.
- The assay detects residual metabolic activity of Cryptococcus neoformans under nutrient-limiting conditions.
- Screened the Library of Pharmacologically Active Compounds (LOPAC) using the developed assay.
Main Results:
- The alamarBlue-based assay successfully identified fungicidal compounds under nutrient-deprived conditions.
- A potential chemical scaffold, 10058-F4, was identified with fungicidal activity in the low micromolar range.
- Demonstrated the effectiveness of the assay for high-throughput screening in identifying anticryptococcal agents.
Conclusions:
- The developed alamarBlue-based assay is feasible for high-throughput screening of fungicidal compounds under nutrient-limiting conditions.
- This approach offers a promising strategy for discovering new anticryptococcal drugs.
- The identified compound 10058-F4 warrants further investigation for cryptococcal meningitis treatment.
